RT Journal Article
SR Electronic
T1 Timing COVID-19 – Synchronization of longitudinal patient data to the underlying disease progression using CRP as a temporal marker
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.11.20128041
DO 10.1101/2020.06.11.20128041
A1 Maibach, Martina A.
A1 Allam, Ahmed
A1 Hilty, Matthias P.
A1 Gonzalez, Nicolas A. Perez
A1 Buehler, Philipp K.
A1 Garcia, Pedro D. Wendel
A1 Brugger, Silvio D.
A1 Ganter, Christoph C.
A1 The CoViD-19 ICU-Research Group Zurich
A1 The RISC-19-ICU Investigators
A1 Krauthammer, Michael
A1 Schuepbach, Reto A.
A1 Bartussek, Jan
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128041.abstract
AB Advances in medical technology and IT infrastructure have led to increased availability of continuous patient data that allows investigation of the longitudinal progression of novel and known diseases in unprecedented detail. However, to accurately describe any underlying pathophysiology with longitudinal data, the individual patient trajectories have to be synchronized based on temporal markers. In this study, we use longitudinal data from 28 critically ill ICU COVID-19 patients to compare the commonly used alignment markers “onset of symptoms”, “hospital admission” and “ICU admission” with a novel objective method based on the peak value of inflammatory marker C-reactive protein (CRP). By applying our CRP-based method to align the progression of neutrophils and lymphocytes, we were able to define a pathophysiological window that allowed further risk stratification in our COVID-19 patient cohort. Our data highlights that proper synchronization of patient data is crucial to differentiate severity subgroups and to allow reliable interpatient comparisons.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported from non-restricted grants to Reto A. Schuepbach.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Further use of routinely collected clinical data for this research project was approved by the cantonal ethics committee of Zurich.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed in anonymized form and code generated during the current study are available from the corresponding author on reasonable request. The RISC-19-ICU data set (NCT04357275) is available on reasonable request (https://www.risc-19-icu.net/main-page/how-to-participate). https://www.risc-19-icu.net/main-page/how-to-participate